Compare Box Inc (BOX) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Charles River Laboratories Intl. Inc — how do they compare? Box Inc trades at $32.46 (market cap $4.55B), while Charles River Laboratories Intl. Inc trades at $284.74 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3× Box Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| BOX | CRL | |
|---|---|---|
Market Cap | $4.55B | $13.46B |
Sector | Technology | Health |
52-Week High | $33.60 | $282.00 |
52-Week Low | $21.37 | $145.57 |
Enterprise Value | $5.10B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $33.6, up 1.08% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income reaching $244.62M and a high gross margin of 79.56%. Recent news highlights Box's AI-ready content platform adoption, such as the Quintas Energy partnership announced on July 30, 2026.
The outlook is positive with a $37 consensus price target, but risks include a high P/E of 51.3 and competitive pressures. Earnings beat expectations in two of the last three quarters, supporting growth momentum, though valuation remains elevated relative to peers.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
